Back
Publications about genetic testing for neurological disorders
  1. A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism

A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism

Ana Westenberger, PhD 1 Charles Jourdan Reyes 1 Gerard M. Saranza Valerija Dobricic, PhD 1 Henrike Hanssen 1 Aloysius Domingo, MD 1, 2 Björn-Hergen Laabs 1 Susen Schaake 1 Jelena Pozojevic 1 Aleksandar Rakovic, PhD 1 K Grütz 1 Kimberly Begemann 1 Prof. Uwe Walter, MD 3 Dirk Dressler 4 Dr. Peter Bauer, MD 5 Prof. Arndt Rolfs, MD 5 Alexander Münchau, MD 1 Frank J. Kaiser, PhD 1 Laurie J Ozelius 2 Roland Dominic G Jamora 6 Raymond L Rosales 6 Cid Czarina E. Diesta 7 Katja Lohmann, PhD 1 Norbert Brüggemann, MD 1 Prof. Christine Klein, MD 1
1 University of Luebeck 2 Massachusetts General Hospital 3 University of Rostock 4 Hannover Medical School 5 CENTOGENE AG 6 University of Santo Tomas Hospital, Manila, Philippines 7 Makati Medical Center, Makati City, Philippines
May 03, 2019

Disease expressivity varies widely in many genetic disorders, and identifying the underlying modifiers holds great translational potential. Based on its resources as regards technologies and samples, CENTOGENE is uniquely positioned to significantly contribute to pertinent efforts. One recent example revealed a novel modifier of disease severity and cognitive dysfunction in X-linked dystonia-parkinsonism. The results were published in the highly prestigious journal Annals of Neurology.

Ann Neurol. 2019 Jun;85(6):812-822. doi: 10.1002/ana.25488. Epub 2019 May 3.

Abstract

OBJECTIVE:

X-linked dystonia parkinsonism (XDP) is a neurodegenerative movement disorder caused by a single mutation: SINE-VNTR-Alu (SVA) retrotransposon insertion in TAF1. Recently, a (CCCTCT)n repeat within the SVA insertion has been reported as an age-at-onset (AAO) modifier in XDP. Here we investigate the role of this hexanucleotide repeat in modifying expressivity of XDP.

METHODS:

We genotyped the hexanucleotide repeat in 355 XDP patients and correlated the repeat number (RN) with AAO (n = 295), initial clinical manifestation (n = 294), site of dystonia onset (n = 238), disease severity (n = 28), and cognitive function (n = 15). Furthermore, we investigated i) repeat instability by segregation analysis and Southern blotting using postmortem brain samples from two affected individuals and ii) relative TAF1 expression in blood RNA from 31 XDP patients.

RESULTS:

RN showed significant inverse correlations with AAO and with TAF1 expression and a positive correlation with disease severity and cognitive dysfunction. Importantly, AAO (and not RN) was directly associated with whether dystonia or parkinsonism will manifest at onset. RN was lower in patients affected by mouth/tongue dystonia compared with blepharospasm. RN was unstable across germline transmissions with an overall tendency to increase in length and exhibited somatic mosaicism in brain.

INTERPRETATION:

The hexanucleotide repeat within the SVA insertion acts as a genetic modifier of disease expressivity in XDP. RN-dependent TAF1 repression and subsequent differences in TAF1 mRNA levels in patients may be potentiated in the brain through somatic variability leading to the neurological phenotype. ANN NEUROL 2019;85:812-822.